Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | MAOB | P27338 | 8/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7600910 | 0.85 | MAPT (0.50) | ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL4454971 | 0.84 | ALDH1A1 (0.47) | ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL9056199 | 0.81 | ALDH1A1 (0.55) | ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL29116198 | 0.81 | ALDH1A1 (0.55) | ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL30649150 | 0.81 | ALDH1A1 (0.59) | ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5679743 | 0.81 | PTPN1 (0.61) | ALDH1A1MAOBMAOAGAAMAPT | |
| SCHEMBL14384453 | 0.81 | PTPN1 (0.61) | ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL8773392 | 0.81 | ALDH1A1 (0.59) | ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL17734362 | 0.81 | PTPN1 (0.61) | ALDH1A1MAOBMAOATHRBGAA | |
| SCHEMBL16982170 | 0.81 | ALDH1A1 (0.55) | ALDH1A1CYP3A4CYP2D6CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | SMITH CHARLES D (US) | 2004-01-22 | — | — | US | claimed |
| EP-4680612-A1 | CHEMICAL COMPOUNDS | AN2 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4611899-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | Petra Pharma Corporation (US) | 2025-09-10 | — | — | EP | disclosed |
| WO-2024192309-A1 | CHEMICAL COMPOUNDS | REACTIVE BIOSCIENCES, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024097172-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION (US) | 2024-05-10 | — | — | WO | disclosed |
| CN-117597343-A | Allosteric ketene inhibitors of phosphoinositide 3-kinase (PI 3K) for the treatment of disease | 佩特拉制药公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | LOXO ONCOLOGY, INC. | 2024-01-18 | — | — | US | disclosed |
| US-9718799-B2 | 3-aryl-4H-chromene-4-ones as antineoplastic agents for the treatment of cancer | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2017-08-01 | — | — | US | disclosed |
| US-20160332981-A1 | 3-ARYL-4H-CHROMENE-4-ONES AS ANTINEOPLASTIC AGENTS FOR THE TREATMENT OF CANCER | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2016-11-17 | — | — | US | disclosed |
| US-7732416-B2 | For protecting plants against parasitic feeding pests; also against the infestation of pets, especially cats and dogs, by fleas, ticks and nematodes; pesticides for crop protection | MERIAL LIMITED (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | disclosed |
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | RENOVIS, INC. | 2006-09-28 | — | — | US | disclosed |
| WO-2004064842-A1 | AMIDE AND ESTER MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| WO-2004014384-A2 | CYCLIC COMPOUNDS CONTAINING ZINC BINDING GROUPS AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | SMITH CHARLES D (US) | 2004-01-22 | — | — | US | disclosed |
| US-4153707-A | Fungicidal isoxazolyl phenols and method of use | THE UPJOHN COMPANY (US) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060217448-A1 | e.g. 4-benzyl-N-[2-(2-chlorophenyl)ethyl]-4,7,9-triazabicyclo[4.4.0]deca-7,9,11-triene-10-carboxamide; antiinflammatory and analgesic agent; rheumatoid arthritis, osteoarthritis, Parkinson's disease, uveitis, asthma, cardiovascular conditions, myocardial infarction | PARK7, UACA, PTGER4 | ALDH1A1 1289/4885CYP3A4 1125/4885CYP2D6 1291/4885 |
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | ALDH1A1 3640/4885CYP3A4 1221/4885CYP2D6 1155/4885 |
| US-20240018115-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | ALDH1A1 3412/4885CYP3A4 610/4885CYP2D6 933/4885 |
| US-20040014764-A1 | N-myristoyltransferase inhibitor compositions and methods of use | NMT2, NMT1, MBOAT1 | ALDH1A1 4793/4885CYP3A4 3885/4885CYP2D6 3487/4885 |
| US-20160332981-A1 | 3-ARYL-4H-CHROMENE-4-ONES AS ANTINEOPLASTIC AGENTS FOR THE TREATMENT OF CANCER | KLK3, NCOA3, CYP46A1 | ALDH1A1 482/4885CYP3A4 101/4885CYP2D6 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.